Can common heart drugs stay safe during a crisis? a trial investigates
NCT ID NCT06453577
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This trial examines how two standard heart failure medications—bisoprolol (a beta blocker) and SGLT2 inhibitors (dapagliflozin or empagliflozin)—are processed by the body during an acute decompensated heart failure episode. Researchers will measure drug levels and heart function in 33 participants both during the acute phase and after stabilization. The goal is to provide evidence-based dosing recommendations for these drugs in a critical care setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bisoprolol and SGLT2 inhibitors (dapagliflozin or empagliflozin)
- What this could lead to
- If successful, this could provide clear dosing guidance for continuing bisoprolol and SGLT2 inhibitors during acute heart failure episodes, potentially improving safety and outcomes.
- What could go wrong
- This is a small, early-phase study (33 participants) focused on drug levels and short-term effects, not long-term outcomes. Results may not apply to all heart failure patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE DECOMPENSATED HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, University Hospital Saarland, Saarland University
Homburg, 66421, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Are heart failure patients taking their meds? a urine test at the ER aims to find out
- Heart failure fluid removal device trial halted early
- Massive new registry aims to unlock secrets of deadly heart shock
- Heart failure study aims to tailor treatments using biomarkers
- New device automates fluid removal in heart failure – could it be a game changer?
- New device could help doctors better manage fluid in heart failure patients